Overview of American Cancer Society Funding Best Practices

THURSDAY, OCTOBER 4, 2018 | 11 A.M. – 5 P.M.

Roseman University of Health Sciences
Summerlin Campus
One Breakthrough Way, Las Vegas
Las Vegas, NV 89147

Michael Melner, PhD, Director of the Molecular Genetics and Biochemistry of Cancer program in the Extramural Grants department at the American Cancer Society, will present an overview of ACS funding opportunities, processes, and best practices in securing American Cancer Society funding.

We will also hear from Thomas Graeber, PhD, Professor, Molecular and Medical Pharmacology, and Director, UCLA Metabolomics Center. Dr. Graeber will speak about his work as a cancer researcher and the outlook for basic science and personalized medicine guiding future therapeutic advances. He will share his perspective on the methods and infrastructure required to execute top quality research and explore ways we can build Nevada’s cancer research community.

Following the presentation, local research projects will be displayed at an informal networking reception.

Please contact Denise Keegan at denise.keegan@cancer.org for an application to display your research board. Space may be limited and available on a first come, first served basis.


11 a.m. – Registration and welcome reception with light snacks
Noon – Opening Comments by Renee Coffman PhD, RPh
12:30-3:30 p.m. – Presentations by Dr. Michael Melner and Dr. Thomas Graeber
4-5 p.m. – Research showcase and reception

To attend, please RSVP to Dr. Coffman at rcoffman@roseman.edu.

Michael Melner, PhD
Michael Melner, PhD, has served as Director of the Molecular Genetics and Biochemistry of Cancer program in the Extramural Grants department of the American Cancer Society since 2006. Dr. Melner is responsible for three Peer Review Committees: DNA Mechanisms of Cancer, RNA Mechanisms in Cancer, and Tumor Biochemistry and Endocrinology. His research interests have been primarily in reproductive endocrinology, examining signal transduction and the molecular mechanisms of transcriptional regulation.

Dr. Melner received his PhD in endocrinology from the Medical College of Georgia in 1980 and served as a National Cancer Institute Postdoctoral Fellow at Vanderbilt University for three years. He was an Assistant Professor at the University of Miami School of Medicine from 1983-1987, an Associate Professor at Oregon Health Sciences University and the Oregon National Primate Center from 1987-1993,and then a Professor at Vanderbilt University from 1993-2006.

Dr. Melner has published 75 papers in scientific journals and served as an editor for the journal Endocrinology for five years and an associate editor for the Journal of Molecular Endocrinology for two years. He has also served on Peer Review Committees for the National Institute of Health, the National Science Foundation, and the Canadian Institutes of Health Research. At the American Cancer Society, Dr. Melner also serves as liaison between the research department and the California and New England Divisions. In his spare time, he enjoys rock climbing on the bullet-hard sandstone of the Southeast.

Thomas Graeber, PhD
Thomas Graeber, PhD, is Director, UCLA Metabolomics Center, and Professor, Molecular and Medical Pharmacology. Dr. Graeber received his B.S. in Physics from UCLA and his PhD in Physics/Cancer Biology from Stanford University, where he studied the role of p53 in hypoxia-induced apoptosis. He did postdoctoral fellowships in signal transduction and in bioinformatics and proteomics, investigating oncogenic autocrine and kinase signaling. He is a member of the Crump Institute for Molecular Imaging, a Research Fellow in Computational Molecular Biology for the Alfred P. Sloan Foundation, and an American Cancer Society Research Scholar.

Dr. Graeber takes an interdisciplinary “systems biology” approach that merges biology, chemistry, mathematics and computation/bioinformatics to understand how cancer cells communicate with their environments, process nutrients, and evade therapies. The ultimate goal of this work is to identify new ways to diagnose and treat cancer on a cellular, patient-specific level.

With numerous publications, Dr. Graeber’s work is funded not only by the American Cancer Society, but also W.M. Keck Foundation, the National Institutes of Health, the UCLA Specialized Program of Research Excellence (SPORE) in Prostate Cancer, a Metabolism Theme Award from the UCLA David Geffen School of Medicine, the UCLA Clinical and Translational Science Institute, and the UCLA Broad Stem Cell Research Center, including support from the Hal Gaba Director’s Fund for Cancer Stem Cell Research. He also received the American Cancer Society’s Giants of Science Passion Award in 2017.